Tuberculosis in People Living with HIV

Svetlana Degtyareva; Scott Heysell; Nashaba Matin; Zelalem Temesgen; Marc Lipman

doi:10.1007/978-3-030-66703-0_24

Tuberculosis in People Living with HIV

Svetlana Degtyareva, Scott Heysell, Nashaba Matin, Zelalem Temesgen, Marc Lipman

Infectious Diseases

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection occurs throughout the world, and remains a significant challenge to TB control. Both HIV and TB cause immune dysregulation that can result in atypical clinical and radiological presentation, and accelerated disease progression. Outcomes with advanced HIV and TB, therefore, can be poor. Whilst antiretroviral drug therapy is crucial, drug-drug interactions and immune reconstitution disease make treatment difficult. The joint effort of healthcare programmes, non-governmental organisations and civil society are needed to ensure the necessary access to testing, prevention and treatment that can reduce the burden of TB/HIV co-infection.

Original language	English (US)
Title of host publication	Essential Tuberculosis
Publisher	Springer International Publishing
Pages	213-220
Number of pages	8
ISBN (Electronic)	9783030667030
ISBN (Print)	9783030667054
DOIs	https://doi.org/10.1007/978-3-030-66703-0_24
State	Published - Jan 1 2021

Keywords

Co-infection
Diagnostic tests
Drug–drug interactions
Extra-pulmonary tuberculosis
GeneXpert
HIV-associated tuberculosis
IRIS
Immunosuppression
LAM test
Latent TB infection
Mycobacteraemia

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1007/978-3-030-66703-0_24

Cite this

@inbook{8abc12c1c82247f19fddaea407857bf7,

title = "Tuberculosis in People Living with HIV",

abstract = "Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection occurs throughout the world, and remains a significant challenge to TB control. Both HIV and TB cause immune dysregulation that can result in atypical clinical and radiological presentation, and accelerated disease progression. Outcomes with advanced HIV and TB, therefore, can be poor. Whilst antiretroviral drug therapy is crucial, drug-drug interactions and immune reconstitution disease make treatment difficult. The joint effort of healthcare programmes, non-governmental organisations and civil society are needed to ensure the necessary access to testing, prevention and treatment that can reduce the burden of TB/HIV co-infection.",

keywords = "Co-infection, Diagnostic tests, Drug–drug interactions, Extra-pulmonary tuberculosis, GeneXpert, HIV-associated tuberculosis, IRIS, Immunosuppression, LAM test, Latent TB infection, Mycobacteraemia",

author = "Svetlana Degtyareva and Scott Heysell and Nashaba Matin and Zelalem Temesgen and Marc Lipman",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2021",

month = jan,

day = "1",

doi = "10.1007/978-3-030-66703-0_24",

language = "English (US)",

isbn = "9783030667054",

pages = "213--220",

booktitle = "Essential Tuberculosis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Tuberculosis in People Living with HIV

AU - Degtyareva, Svetlana

AU - Heysell, Scott

AU - Matin, Nashaba

AU - Temesgen, Zelalem

AU - Lipman, Marc

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2021.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection occurs throughout the world, and remains a significant challenge to TB control. Both HIV and TB cause immune dysregulation that can result in atypical clinical and radiological presentation, and accelerated disease progression. Outcomes with advanced HIV and TB, therefore, can be poor. Whilst antiretroviral drug therapy is crucial, drug-drug interactions and immune reconstitution disease make treatment difficult. The joint effort of healthcare programmes, non-governmental organisations and civil society are needed to ensure the necessary access to testing, prevention and treatment that can reduce the burden of TB/HIV co-infection.

AB - Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection occurs throughout the world, and remains a significant challenge to TB control. Both HIV and TB cause immune dysregulation that can result in atypical clinical and radiological presentation, and accelerated disease progression. Outcomes with advanced HIV and TB, therefore, can be poor. Whilst antiretroviral drug therapy is crucial, drug-drug interactions and immune reconstitution disease make treatment difficult. The joint effort of healthcare programmes, non-governmental organisations and civil society are needed to ensure the necessary access to testing, prevention and treatment that can reduce the burden of TB/HIV co-infection.

KW - Co-infection

KW - Diagnostic tests

KW - Drug–drug interactions

KW - Extra-pulmonary tuberculosis

KW - GeneXpert

KW - HIV-associated tuberculosis

KW - IRIS

KW - Immunosuppression

KW - LAM test

KW - Latent TB infection

KW - Mycobacteraemia

UR - http://www.scopus.com/inward/record.url?scp=85160486476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85160486476&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-66703-0_24

DO - 10.1007/978-3-030-66703-0_24

M3 - Chapter

AN - SCOPUS:85160486476

SN - 9783030667054

SP - 213

EP - 220

BT - Essential Tuberculosis

PB - Springer International Publishing

ER -

Tuberculosis in People Living with HIV

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this